<?xml version='1.0' encoding='utf-8'?>
<document id="28885219"><sentence text="Recognition of possible risk factors for clinically significant drug-drug interactions among Indian people living with HIV receiving highly active antiretroviral therapy and concomitant medications." /><sentence text="Greatest challenges for clinician is to recognize risk factors for clinically significant drug interactions (CSDIs)" /><sentence text=" There is a lack of awareness about CSDIs among healthcare professionals in India" /><sentence text="" /><sentence text="To recognize all possible risk factors for drug-drug interactions (DDIs) and to identify clinically significant drug interactions (CSDIs), the prevalence, pattern of occurrence of DDIs in People Living with HIV (PLW-HIV) receiving highly active antiretroviral therapy (HAART) and concomitant medications" /><sentence text="" /><sentence text="A retrospective medical record review was carried out by clinical pharmacist with ethics committee approval" /><sentence text=" Case files of HIV patients receiving HAART with concomitant medications were analyzed for CSDIs using University of Liverpool drug interaction database and CSDIs were classified based on red flag indication (RFI) or contraindicated drug-drug interaction (XDDIs) and orange flag indication (OFI) or DDIs that needs close monitoring" /><sentence text=" Patients with DDIs (cases) and patients without DDIs (controls) were compared with Chi-square tests" /><sentence text=" P value &lt;0" /><sentence text="05 was considered as statistically significant" /><sentence text="" /><sentence text="A total of 240 HIV patients' cases were screened" /><sentence text=" Out of which 267 DDIs were reported in 107 patients" /><sentence text=" Prevalence of DDIs was higher in male 71 (66" /><sentence text="4%) compared to female 36 (33" /><sentence text="6%)" /><sentence text=" On zero-inflated poisson regression analysis, factors of polypharmacy, opportunistic infections, comorbid condition like Ischemic heart disease, respiratory tract infections, and psychiatric disorder were found to be predictors of high risk factors for DDIs to HAART" /><sentence text=" Fourteen XDDIs with RFI and two hundred fifty three DDIs with OFI were reported" /><sentence text=" XDDIs were atazanavir with fluconazole 4 (28"><entity charOffset="12-22" id="DDI-PubMed.28885219.s20.e0" text="atazanavir" /><entity charOffset="28-39" id="DDI-PubMed.28885219.s20.e1" text="fluconazole" /><pair ddi="false" e1="DDI-PubMed.28885219.s20.e0" e2="DDI-PubMed.28885219.s20.e0" /><pair ddi="false" e1="DDI-PubMed.28885219.s20.e0" e2="DDI-PubMed.28885219.s20.e1" /></sentence><sentence text="6%), ritonavir with fluconazole 4 (28"><entity charOffset="5-14" id="DDI-PubMed.28885219.s21.e0" text="ritonavir" /><entity charOffset="20-31" id="DDI-PubMed.28885219.s21.e1" text="fluconazole" /><pair ddi="false" e1="DDI-PubMed.28885219.s21.e0" e2="DDI-PubMed.28885219.s21.e0" /><pair ddi="false" e1="DDI-PubMed.28885219.s21.e0" e2="DDI-PubMed.28885219.s21.e1" /></sentence><sentence text="6%), nevirapine with rifampicin 2 (14"><entity charOffset="5-15" id="DDI-PubMed.28885219.s22.e0" text="nevirapine" /><entity charOffset="21-31" id="DDI-PubMed.28885219.s22.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.28885219.s22.e0" e2="DDI-PubMed.28885219.s22.e0" /><pair ddi="false" e1="DDI-PubMed.28885219.s22.e0" e2="DDI-PubMed.28885219.s22.e1" /></sentence><sentence text="4%), ritonavir with quetiapine, atazanavir with pantoprazole"><entity charOffset="5-14" id="DDI-PubMed.28885219.s23.e0" text="ritonavir" /><entity charOffset="20-30" id="DDI-PubMed.28885219.s23.e1" text="quetiapine" /><entity charOffset="32-42" id="DDI-PubMed.28885219.s23.e2" text="atazanavir" /><entity charOffset="48-60" id="DDI-PubMed.28885219.s23.e3" text="pantoprazole" /><pair ddi="false" e1="DDI-PubMed.28885219.s23.e0" e2="DDI-PubMed.28885219.s23.e0" /><pair ddi="false" e1="DDI-PubMed.28885219.s23.e0" e2="DDI-PubMed.28885219.s23.e1" /><pair ddi="false" e1="DDI-PubMed.28885219.s23.e0" e2="DDI-PubMed.28885219.s23.e2" /><pair ddi="false" e1="DDI-PubMed.28885219.s23.e0" e2="DDI-PubMed.28885219.s23.e3" /><pair ddi="false" e1="DDI-PubMed.28885219.s23.e1" e2="DDI-PubMed.28885219.s23.e1" /><pair ddi="false" e1="DDI-PubMed.28885219.s23.e1" e2="DDI-PubMed.28885219.s23.e2" /><pair ddi="false" e1="DDI-PubMed.28885219.s23.e1" e2="DDI-PubMed.28885219.s23.e3" /><pair ddi="false" e1="DDI-PubMed.28885219.s23.e2" e2="DDI-PubMed.28885219.s23.e2" /><pair ddi="false" e1="DDI-PubMed.28885219.s23.e2" e2="DDI-PubMed.28885219.s23.e3" /></sentence><sentence text=" Pharmacokinetic DDIs were highest 238 (89" /><sentence text="1%)" /><sentence text=" Sixteen DDIs were reported in a single patient" /><sentence text=" The majority 97 (90" /><sentence text="6%) patients had developed ≤5 DDIs, 8 (7" /><sentence text="5%) developed six to eleven DDIs" /><sentence text=" The highest DDIs were reported with efavirenz 49 (18"><entity charOffset="37-46" id="DDI-PubMed.28885219.s30.e0" text="efavirenz" /></sentence><sentence text="4%) and zidovudine 44 (16"><entity charOffset="8-18" id="DDI-PubMed.28885219.s31.e0" text="zidovudine" /></sentence><sentence text="5%) based HAART regimen" /><sentence text="" /><sentence text="In India, with the increasing access to HAART usage, Clinician must focus to pay attention to recognize possible risk factors for CSDIs associated with HAART regimen and strictly to avoid &quot;Red Flag Indication combinations&quot; while prescribing so as to prevent CSDIs" /><sentence text="" /></document>